On this page
Quick Reference
Overview and Recommendations
Background
- •Bell palsy is an acute, idiopathic, unilateral lower motor neuron facial nerve palsy, accounting for approximately 75% of all acute peripheral facial paralyses and affecting 20-30 per 100,000 persons annually worldwide. It carries significant functional and psychosocial morbidity during the acute phase, but complete spontaneous recovery occurs in about 70% of untreated patients within 3-6 months.
- •The condition is named after Sir Charles Bell, the Scottish anatomist who first described the facial nerve's role in facial expression. It is also called idiopathic facial nerve palsy, a term that underscores its unknown cause; the non-possessive form 'Bell palsy' is preferred in contemporary medical literature.
- •The pathogenetic paradigm centers on an inflammatory demyelinating neuritis, likely triggered by herpes simplex virus type 1 reactivation within the geniculate ganglion, leading to edema and secondary ischemic compression of the facial nerve within the rigid fallopian canal. The labyrinthine segment (0.68 mm diameter) is the narrowest and most vulnerable site.
- •Despite being self-limiting, Bell palsy is a clinical emergency: early treatment with prednisolone 1 mg/kg/day (max 60 mg) for 10 days improves the rate of complete recovery at 3 months from 70% to 85% (number needed to treat [NNT] = 7), and delayed therapy beyond 72 hours is associated with significantly worse outcomes.
- •Severity is graded using the House-Brackmann scale (I-VI). Grade I is normal, grade VI is total paralysis. This grading guides prognosis and treatment decisions, including the threshold for considering electroneuronography (ENoG) and surgical decompression in complete paralysis with >90% denervation within 14 days.
- •Bell palsy can mimic stroke (the most common stroke mimic), and up to 30% of patients develop residual synkinesis or hemifacial spasm due to aberrant nerve regeneration. Long-term sequelae, though often mild, can cause persistent functional impairment and cosmetic concern requiring botulinum toxin therapy.
Evaluation
- •Suspect Bell palsy in any patient presenting with acute (<72 hours), unilateral facial weakness involving both the upper and lower face (forehead is affected), with ipsilateral effacement of the nasolabial fold, widened palpebral fissure, and drooping of the mouth corner.
- •Ask about onset timing (sudden vs. gradual), associated symptoms: ear pain, hyperacusis, taste disturbance (dysgeusia or ageusia on the anterior two-thirds of the tongue), decreased tearing, and subjective facial numbness (often due to trigeminal nerve overlap rather than true CN V involvement).
- •Also ask for red-flag symptoms: vesicular rash in the ear canal or auricle (suggests Ramsay Hunt syndrome), headache, fever, stiff neck, recent tick bite or erythema migrans (Lyme disease), bilateral or recurrent facial palsy, or concomitant limb weakness/diplopia (suggests central cause or Guillain-Barré syndrome).
- •Examine the face at rest and during voluntary movement: ask the patient to raise eyebrows, close eyes tightly, puff cheeks, and show teeth. Document the House-Brackmann grade (I-VI). Confirm that the forehead is involved, this distinguishes lower motor neuron (Bell palsy) from upper motor neuron (stroke) weakness, which spares the forehead.
- •Inspect the ear canal and tympanic membrane carefully for vesicular lesions (Ramsay Hunt syndrome) and palpate the parotid gland for masses. Perform a full neurological exam including assessment of extraocular movements, hearing, taste on the anterior tongue (if feasible), and testing of CN V, VIII, IX, X, XI, XII for other neuropathies.
- •The diagnosis of Bell palsy is clinical and a diagnosis of exclusion. No routine imaging or laboratory tests are needed if the history and exam are classic and no atypical features are present.
- •Order noncontrast head CT or MRI brain with diffusion-weighted imaging if there is any suspicion of central (upper motor neuron) weakness, especially forehead sparing, associated limb weakness, speech disturbance, or acute headache with vomiting, to rule out ischemic stroke or intracranial hemorrhage. Bell palsy is the most common stroke mimic in both adults and children.
- •Order contrast-enhanced MRI of the internal auditory canal and facial nerve with gadolinium if atypical features are present: gradual progression >3 weeks, age <18 years (to exclude congenital anomalies or tumors), recurrent ipsilateral palsy, bilateral palsy, vesicular rash, fever, parotid mass, or failure to improve after 3 months. In acute Bell palsy, MRI reveals enhancement of the geniculate, labyrinthine, or tympanic segments in up to 90% of patients, but this finding is not specific.
- •Consider serologic testing (Lyme ELISA/Western blot, VZV serology, HIV, ANA, ACE, syphilis) based on exposure history and clinical suspicion. In endemic areas or if there is a history of tick exposure with erythema migrans, test for Lyme disease, as facial palsy may be the presenting feature of early disseminated Lyme in children and adults.
- •Perform electroneuronography (ENoG) and needle electromyography (EMG) in patients with complete paralysis (House-Brackmann grade VI) within 14 days of onset to quantify denervation. A compound muscle action potential (CMAP) amplitude ≤10% of the unaffected side (i.e., ≥90% denervation) predicts poor recovery and defines a narrow window in which surgical decompression is sometimes considered. The presence of voluntary motor unit potentials on needle EMG within the first 10 days is a favorable sign.
- •Also consider Ramsay Hunt syndrome (varicella-zoster virus reactivation) if vesicles are present in the ear canal, auricle, or oral mucosa, or if there is severe otalgia, hearing loss, or vertigo. VZV PCR of vesicular fluid or serum VZV IgM can confirm the diagnosis; treatment requires acyclovir 800 mg 5 times daily for 7-10 days plus corticosteroids.
- •In children, the differential includes acute otitis media (may cause facial palsy from middle ear infection or cholesteatoma), Lyme disease (especially in endemic regions), and stroke. Children with Bell palsy typically recover well, but MRI with contrast is advised if there is no improvement within 3 weeks or if recurrent or bilateral.
Management
- •Initiate oral prednisolone as soon as possible, ideally within 72 hours of symptom onset. Adults: 1 mg/kg/day (maximum 60-80 mg/day) for 7-10 days. No taper is needed for short courses. This is the single most effective intervention: NNT = 7 for complete recovery at 3 months. Treatment beyond 7 days offers no additional benefit.
- •For severe Bell palsy (House-Brackmann grade IV-VI), consider adding oral valacyclovir 1 g three times daily for 7 days (or acyclovir 800 mg five times daily) to prednisolone. The combination provides a modest additional benefit (OR 1.48; NNT = 12) compared with steroids alone, though it is not standard for mild cases. For Ramsay Hunt syndrome, combination therapy is mandatory.
- •Do not prescribe antiviral monotherapy without corticosteroids for Bell palsy, it is no better than placebo and delays effective treatment. Antivirals are reserved for severe cases or when varicella-zoster virus is suspected (Ramsay Hunt syndrome).
- •Do not routinely order MRI or CT for classic Bell palsy. Imaging is reserved for atypical presentations (see Evaluation) and for patients who fail to improve after 3 months, where it reveals an alternative cause in <2% of cases. Overuse of imaging delays treatment and incurs unnecessary cost.
- •Protect the eye in patients with lagophthalmos (incomplete eye closure). Prescribe preservative-free artificial tears every 1-2 hours while awake, a lubricating ophthalmic ointment at bedtime, and tape the eye closed at night or use a moisture chamber. If corneal exposure persists, refer to ophthalmology for temporary tarsorrhaphy or botulinum toxin-induced protective ptosis.
- •Monitor for corneal abrasion and exposure keratopathy. Assess visual acuity and perform fluorescein staining if eye pain, photophobia, or decreased vision occur. Urgent ophthalmology referral for any corneal ulceration or persistent epithelial defect.
- •Counsel patients about recovery expectations: spontaneous improvement typically begins within 3 weeks in 85% of patients; most achieve near-complete recovery by 3-6 months. Prognosis is more guarded if complete paralysis persists beyond 3 weeks without improvement. Residual weakness or synkinesis occurs in up to 30%.
- •For post-Bell palsy synkinesis (e.g., eye closure causing mouth twitching or mouth movement causing eyelid closure), first-line therapy is botulinum toxin A (Botox) injections: 1.25-5 units per injection site into the involved orbicularis oculi or other hyperactive muscles. Effects last 3-4 months and can be repeated. Refer to a neurologist or facial nerve specialist for this.
- •For hemifacial spasm or neuropathic otalgia after Bell palsy, consider gabapentin 300-900 mg daily (titrated as tolerated) or pregabalin 75-150 mg twice daily. If symptoms are severe or persistent, refer to a neurologist for further evaluation (e.g., MRI to exclude vascular compression). Botulinum toxin remains the most effective treatment for hemifacial spasm.
- •Surgical facial nerve decompression is rarely indicated and remains controversial. It may be offered only to patients with: (1) complete paralysis (House-Brackmann grade VI), (2) ENoG showing >90% denervation (CMAP ≤10% of unaffected side) within 14 days of onset, and (3) no spontaneous recovery by day 14. The procedure must be performed within 2-3 weeks of onset to have any potential benefit; beyond that, it does not improve outcomes. Refer to a skull-base surgeon who performs this procedure.
- •Do not perform surgical decompression after 3 weeks from onset, for incomplete paralysis, or for patients with partial recovery, it offers no benefit and risks hearing loss and other complications.
- •Avoid non-dihydropyridine calcium channel blockers (verapamil, diltiazem), tricyclic antidepressants, and SSRIs where possible in patients with comorbid cardiovascular disease because of potential interaction with corticosteroids (hyperglycemia, hypertension). For pain, acetaminophen or ibuprofen are safe; avoid opioids unless severe otalgia.
- •In children, prednisolone 1-2 mg/kg/day (max 60 mg) for 7-10 days is equally effective and safe. A pediatric series showed 98% recovery at 6 months with prednisolone vs. 93% with placebo (absolute difference 5%, NNT = 20, not statistically significant). However, guidelines still recommend steroid treatment given the favorable safety profile and trend toward benefit. Eye protection is equally important.
- •Hospital admission is rarely needed for Bell palsy. Indications include: inability to eat or drink due to severe facial weakness (risk of aspiration), suspected life-threatening alternative diagnosis (e.g., bacterial meningitis, brainstem stroke), need for urgent surgical evaluation (e.g., temporal bone fracture), or need for IV hydration or IV steroids if oral not tolerated.
- •Discharge criteria: no corneal ulceration, patient/caregiver able to provide eye care, ability to take oral medications and maintain oral intake, safe swallow, no signs of alternative acute neurological disease (e.g., stroke). Arrange outpatient follow-up with primary care or neurology in 2-4 weeks to monitor recovery and manage sequelae.
- •Refer to otolaryngology or facial nerve clinic if: no recovery by 3 months, worsening symptoms beyond 2 weeks, recurrent ipsilateral or bilateral palsy, suspected secondary cause (parotid mass, cholesteatoma), or consideration for surgical decompression. Refer to ophthalmology for any corneal complication.
- •Advise against common alternative therapies: acupuncture, facial exercises, electrical stimulation, none have proven benefit and may promote synkinesis. Physical therapy for facial retraining (neuromuscular retraining) may be considered after 3 months if synkinesis or persistent weakness, but evidence is limited. Chiropractic manipulation of the cervical spine is contraindicated (risk of vertebral artery dissection causing stroke).
Board Review — High Yield
- •Forehead-sparing vs. forehead-involved, Bell palsy affects the entire ipsilateral face including the forehead (lower motor neuron); stroke spares the forehead (upper motor neuron).
- •House-Brackmann grade I-VI, Standard severity scale. Grade VI = total paralysis; grade I = normal function.
- •NNT = 7, Prednisolone 1 mg/kg/day × 7-10 days for complete recovery at 3 months (from ~70% to ~85%).
- •Labyrinthine segment, The narrowest region of the fallopian canal (0.68 mm) where entrapment edema occurs; most common site of nerve enhancement on MRI.
- •ENoG cutoff, CMAP ≤10% of unaffected side within 14 days = >90% denervation; predicts poor recovery and defines the window for possible surgical decompression.
- •Ramsay Hunt syndrome, Vesicular rash in ear canal/auricle; requires acyclovir 800 mg 5×/d + prednisolone. Worse prognosis than Bell palsy if untreated.
- •Post-Bell palsy synkinesis, Ocular-oral or oral-ocular; first-line treatment: botulinum toxin A (1.25-5 U per injection site) into involved orbicularis oculi.
- •MRI enhancement pattern, Geniculate ganglion (80%), labyrinthine (60%), tympanic (50%), intracanalicular (40%); not specific, also seen in Ramsay Hunt syndrome and schwannoma.
- •Bilateral facial palsy, Rare (<1%); think Guillain-Barré, sarcoidosis, Lyme, HIV, meningitis. Not Bell palsy.
- •Vaccine association, mRNA SARS-CoV-2 vaccines: reported increased risk (IRR 2.50), absolute risk 0.5-1/10,000; overall low and should not deter vaccination.
Deep Dive — Evidence Details
Definition & Classification
- ▸Bell palsy is defined as acute, unilateral, peripheral facial nerve palsy without identifiable cause, affecting 20-30/100,000 annually.
- ▸Severity is classified via the House-Brackmann grading system (I-VI); May's classification groups outcomes as complete (I), fair (II-III), or failed (IV-VI) recovery.
- ▸Early oral prednisolone (1 mg/kg/day for 10 days) improves complete recovery rates by 15% (NNT = 7) and is first-line therapy.
Bell palsy is an acute, unilateral, peripheral facial nerve palsy of unknown etiology, characterized by rapid-onset weakness of the muscles of facial expression. It is the most common cause of acute facial paralysis, with an annual incidence of 20 to 30 cases per 100,000 persons [5]A1c. The condition is named after Sir Charles Bell, a Scottish anatomist who first described the facial nerve's role in facial expression.
Also Known As
- Idiopathic facial nerve palsy
- Idiopathic facial paralysis
- Facial nerve palsy (Bell palsy specifically)
- Cold palsy (historical, reflecting early belief that cold exposure triggered it)
Classification of Severity
Facial nerve function in Bell palsy is most commonly graded using the House-Brackmann grading system (HBGS), a five-point scale (I-VI) that assesses facial symmetry and voluntary motion at rest and with movement. A validated modification, May's classification, collapses HBGS into three functional outcomes: complete recovery (HBGS I), fair recovery (HBGS II-III), and failed recovery (HBGS IV-VI) [1]A1a.
| Grade | Description | Features |
|---|---|---|
| I | Normal | Normal symmetrical function |
| II | Mild dysfunction | Slight weakness; complete eye closure with minimal effort |
| III | Moderate dysfunction | Obvious weakness; complete eye closure with effort |
| IV | Moderately severe dysfunction | Asymmetry at rest; incomplete eye closure |
| V | Severe dysfunction | Barely perceptible motion; incomplete eye closure |
| VI | Total paralysis | No movement |
Clinical Significance
Bell palsy accounts for approximately 75% of all acute peripheral facial palises and, while often self-limiting, leads to significant functional impairment and psychosocial distress during the acute phase. Timely recognition is critical because outcomes improve with early corticosteroid therapy: treatment with prednisolone 1 mg/kg/day (max 60 mg) for 10 days increases the rate of complete recovery at 3 months from 70% to 85% (number needed to treat [NNT] = 7) [5]A1c.
Pearl: Bell palsy is a diagnosis of exclusion defined by idiopathic acute unilateral peripheral facial weakness; severity is graded with the House-Brackmann scale (I-VI), and early prednisolone 1 mg/kg/day for 10 days is standard care (NNT = 7 for complete recovery at 3 months) [5]A1c.
| Grade | Description | Features | May's Class |
|---|---|---|---|
| I | Normal | Normal symmetrical function | Complete recovery |
| II | Mild dysfunction | Slight weakness; complete eye closure with minimal effort | Fair recovery |
| III | Moderate dysfunction | Obvious weakness; complete eye closure with effort | Fair recovery |
| IV | Moderately severe dysfunction | Asymmetry at rest; incomplete eye closure | Failed recovery |
| V | Severe dysfunction | Barely perceptible motion; incomplete eye closure | Failed recovery |
| VI | Total paralysis | No movement | Failed recovery |
Source: [1]A1a
Gross Structure & Morphology
- ▸The facial nerve's labyrinthine segment is the narrowest and most vulnerable to compression-induced ischemia and demyelination in Bell palsy.
- ▸Histopathological changes include intraneural fibrosis, axonal degeneration, and demyelination, with severity dependent on duration of entrapment.
- ▸Bilateral morphological alterations in fungiform papillae (atrophy, vascular changes) occur even in clinically unilateral Bell palsy, indicating subclinical bilateral nerve involvement.
The facial nerve's intratemporal course, from the internal auditory meatus through the fallopian canal to the stylomastoid foramen, renders it uniquely vulnerable to compression and ischemia in Bell palsy. The nerve is encased in a bony canal that is narrowest at the labyrinthine segment (mean diameter 0.68 mm), where even mild edema can critically impair microcirculation and axonal transport [8]B2b. This anatomical bottleneck explains why the labyrinthine segment is the most common site of nerve swelling and subsequent degeneration in acute palsy.
Segmental Anatomy and Pathological Changes
The facial nerve is divided into five segments: intracranial, meatal, labyrinthine, tympanic, and mastoid. The labyrinthine segment, measuring only 4-5 mm in length, is the most constricted and is the primary locus of entrapment. In Bell palsy, histopathological studies from animal models (rat ligation model) demonstrate that sustained compression leads to intraneural fibrosis, demyelination, and axonal degeneration within 1-3 weeks of onset [8]B2b. The degree of fibrosis correlates with the timing of decompression: earlier intervention (within 1 week) reduces fibrotic changes and improves nerve regeneration [8]B2b.
Morphological Alterations in Distal Targets
Beyond the nerve trunk, Bell palsy induces morphological changes in the peripheral structures it innervates. The chorda tympani branch, which carries taste fibers to the anterior two-thirds of the tongue, undergoes retrograde degeneration that alters the morphology of fungiform papillae. In patients with unilateral Bell palsy, bilateral examination of the anterior tongue reveals atrophy of fungiform papillae and vascular changes (e.g., reduced capillary density) on both the affected and contralateral sides, suggesting subclinical bilateral involvement of the facial nerve [6]B2b. These morphological changes correlate with electrogustometric thresholds and chemogustometry scores, indicating that taste bud structure is directly affected by nerve injury [6]B2b.
Cortical Correlates of Nerve Injury
Although not a direct component of the facial nerve's gross structure, the primary motor cortex (M1) contralateral to the paretic face undergoes measurable morphometric changes during recovery. Longitudinal voxel-based morphometry in a single patient showed an initial increase in gray matter concentration in the face area of M1, followed by normalization as motor function returned [7]C4. This cortical plasticity reflects the peripheral nerve's structural insult and subsequent reorganization.
| Segment | Length (approx.) | Vulnerability | Key Morphological Change in Bell Palsy |
|---|---|---|---|
| Labyrinthine | 4-5 mm | Highest | Edema, demyelination, axonal degeneration [8]B2b |
| Tympanic | 8-11 mm | Moderate | Compression, vascular congestion |
| Mastoid | 10-14 mm | Low | Fibrosis (if prolonged) [8]B2b |
Pearl: The labyrinthine segment's bony confinement makes it the epicenter of nerve injury in Bell palsy; early decompression within 1 week reduces intraneural fibrosis and improves axonal regeneration, while bilateral taste bud atrophy underscores subclinical nerve involvement [6]B2b[8]B2b.
Relations, Borders & Spaces
- ▸The facial nerve's labyrinthine segment is the narrowest and most vulnerable to compression in Bell palsy
- ▸Tympanic segment dehiscence (10-25%) places CN VII at risk during middle-ear surgery
- ▸The posterior belly of the digastric muscle is the reliable surgical landmark for identifying the main trunk exiting the stylomastoid foramen
The facial nerve (CN VII) emerges from the brainstem at the pontomedullary junction, immediately lateral to the abducens nerve (CN VI) and medial to the vestibulocochlear nerve (CN VIII). This cisternal segment (approximately 23 mm long) courses anterolaterally across the cerebellopontine angle cistern, sandwiched between the anterior inferior cerebellar artery (AICA), which loops around the nerve in 64% of individuals, and the choroid plexus of the fourth ventricle [9]D5[10]B3b. The nerve then enters the internal acoustic meatus, where it occupies the anterosuperior quadrant, with CN VIII posterior and the nervus intermedius (the nerve's sensory and parasympathetic root) interposed between them.
Intratemporal Course and Key Landmarks
The meatal segment (8-12 mm) gives way to the labyrinthine segment (3-5 mm), the narrowest and most vulnerable portion of the fallopian canal. Here the nerve lies directly beneath the geniculate ganglion, a key surgical and imaging landmark visible on high-resolution CT as a lucent depression in the petrous bone [10]B3b. The tympanic segment (11 mm) runs horizontally along the medial wall of the middle ear, just superior to the oval window and cochleariform process; dehiscence of the bony canal occurs in 10-25% of temporal bones, placing the nerve at risk during middle-ear surgery. The mastoid segment (13-16 mm) descends vertically, passing between the facial recess and the fossa incudis before exiting the skull base through the stylomastoid foramen [9]D5[10]B3b.
Extratemporal Relations
After exiting the stylomastoid foramen, the nerve turns anteriorly to enter the parotid gland, where it bifurcates into upper (temporofacial) and lower (cervicofacial) divisions. This extratemporal segment (15-20 mm) lies superficial to the stylohyoid and posterior belly of the digastric muscle, a reliable surgical landmark for locating the main trunk during parotidectomy or nerve repair [9]D5. The nerve's intimate relation with the parotid parenchyma explains why parotid tumors, abscesses, or iatrogenic injury during gland surgery produce ipsilateral facial weakness. Within the parotid, five terminal branches (temporal, zygomatic, buccal, marginal mandibular, and cervical) emerge and arborize across the superficial musculoaponeurotic system (SMAS), each supplying defined territories [9]D5[10]B3b.
Surgical and Imaging Correlates
| Landmark | Anatomic Relation | Clinical Relevance |
|---|---|---|
| Stylomastoid foramen | 6-10 mm posterior to the mastoid tip | Target for nerve block or decompression |
| Tympanic segment | Medial to incus, superior to oval window | Vulnerable during resection |
| Geniculate ganglion | Adjacent to the greater superficial petrosal nerve | Epicenter for geniculate ganglion neuralgia |
Pearl: The labyrinthine segment's bony fallopian canal is the narrowest (0.68 mm diameter) and lacks a paraneural sheath, making it the most common site of entrapment edema in Bell palsy, explaining why early decompression at this site may improve recovery in select candidates [9]D5[10]B3b.
Blood Supply, Innervation & Lymphatic Drainage
- ▸The facial nerve arterial supply is segmental (labyrinthine, superior petrosal, and stylomastoid arteries), with a critical watershed at the geniculate ganglion making it vulnerable to ischaemic compression in Bell palsy.
- ▸Venous drainage of the intratemporal nerve relies on the stylomastoid vein; congestion within the rigid fallopian canal can worsen oedema and propagate nerve injury.
- ▸The nerve lacks intratemporal lymphatic drainage; any associated lymphadenopathy (parotid or cervical) strongly suggests an alternative diagnosis.
Arterial Supply of the Facial Nerve
The facial nerve (CN VII) is supplied along its course by three principal arterial systems, making it vulnerable to ischaemia at watershed zones. Within the internal auditory meatus, the labyrinthine artery (a branch of the anterior inferior cerebellar artery, AICA) supplies the nerve. The geniculate ganglion and the horizontal (tympanic) segment receive blood from the superior petrosal branch of the middle meningeal artery. The mastoid and extratemporal segments are perfused by the stylomastoid artery, a branch of the posterior auricular artery (occasionally from the occipital artery) [11]D5. This segmental supply creates a critical watershed at the geniculate ganglion, a site where oedema in Bell palsy can precipitate nerve compression and ischaemic injury.
The stylomastoid artery enters the stylomastoid foramen with the facial nerve and anastomoses with the superior petrosal branch, forming a longitudinal plexus along the fallopian canal. Venous drainage parallels the arterial supply, emptying into the pterygoid plexus, the sigmoid sinus, and the superior petrosal sinus via the vein of the cochlear aqueduct.
Venous Drainage and the Role of Venous Congestion
Venous drainage of the facial nerve within the fallopian canal depends on the stylomastoid vein, which drains into the retromandibular vein and the external jugular system. The bony, inextensible fallopian canal means that any increase in venous pressure (e.g., from inflammation, thrombosis, or external compression) can rapidly impair perfusion, contributing to the oedema-ischaemia cycle that is hypothesised in the pathogenesis of Bell palsy [6]B2b. There is no dedicated lymphatic drainage within the intratemporal facial nerve; lymph from the surrounding temporal bone drains to the parotid and retropharyngeal nodes, which are therefore relevant only when the differential includes neoplastic or infectious facial nerve involvement.
Innervation of the Nerve's Own Vasa Nervorum
The extrinsic and intrinsic blood vessels of the facial nerve are innervated by sympathetic fibres from the superior cervical ganglion, which travel with the external carotid artery plexus. These vasomotor fibres regulate perfusion pressure within the vasa nervorum; any interruption, such as from viral neuritis or surgical manipulation, can cause local ischaemia. The absence of parasympathetic innervation to the vasa nervorum means that vasodilation is limited, further predisposing the nerve to ischaemic injury during episodes of oedema.
Lymphatic Drainage and Its Clinical Relevance
The parotid gland, through which the extratemporal facial nerve passes, contains a rich lymphatic network. The superficial parotid nodes receive lymph from the lateral face and the external ear, while the deep parotid nodes drain into the upper deep cervical chain (level II). In Bell palsy, these nodes are not typically enlarged; their palpation or pathological enlargement should prompt a search for an alternative diagnosis (e.g., parotid malignancy, sarcoidosis, or ).
| Structure | Arterial Supply | Venous Drainage | Lymphatic Drainage | Clinical Point |
|---|---|---|---|---|
| Intracanalicular segment | Labyrinthine artery (AICA) | Vein of cochlear aqueduct → superior petrosal sinus | None intratemporal | Watershed at geniculate; viral oedema blocks perfusion [11]D5 |
| Tympanic & geniculate segments | Superior petrosal branch (middle meningeal artery) | Pterygoid plexus | Parotid nodes | Compression in fallopian canal causes ischaemia |
| Mastoid segment | Stylomastoid artery (posterior auricular) | Stylomastoid vein → retromandibular vein | Upper deep cervical nodes (level II) | Venous congestion worsens oedema |
| Extratemporal branches | Stylomastoid artery + superficial temporal + facial artery | Facial vein → internal jugular vein | Parotid and submandibular nodes | Nodal enlargement suggests alternative diagnosis |
Pearl: The facial nerve's segmental blood supply creates a watershed at the geniculate ganglion, a site exquisitely vulnerable to ischaemia when oedema raises intratemporal pressure; lack of a dedicated intratemporal lymphatic network means that any palpable lymphadenopathy in Bell palsy should prompt urgent evaluation for alternative causes such as parotid tumour or sarcoidosis [6]B2b[11]D5.
Microscopic & Histological Notes
- ▸Bell palsy histology shows inflammatory demyelinating neuritis with perivascular lymphocytic infiltration centered on the labyrinthine and geniculate segments of the facial nerve.
- ▸Luxol fast blue staining reveals segmental demyelination; Bielschowsky silver stain demonstrates axonal loss in chronic cases.
- ▸Absence of intranuclear inclusions, granulomas, or spirochetes distinguishes Bell palsy from Ramsay Hunt syndrome, sarcoidosis, and Lyme neuroborreliosis.
The histology of the involved facial nerve in Bell palsy is defined by an inflammatory demyelinating process centered on the intratemporal segment, particularly the labyrinthine and geniculate portions [15]C4. Biopsy and autopsy specimens reveal perivascular and interstitial mononuclear cell infiltration, predominantly lymphocytes and macrophages, surrounding nerve bundles. Edema within the tight osseous confines of the fallopian canal contributes to secondary axonal compression and Wallerian degeneration distal to the site of inflammation.
Key Histopathological Findings
- Demyelination: Segmental loss of myelin sheaths is the earliest change, visible on Luxol fast blue (LFB) staining as pale, disrupted blue rings around axons. Macrophages engulf myelin debris, seen as periodic acid-Schiff ( )-positive granules within foamy cytoplasm.
- Edema and congestion: Endoneurial edema separates individual nerve fibers. The surrounding epineurium may show capillary dilation and red blood cell extravasation, though frank hemorrhage is rare.
- Chronic changes: In patients with incomplete recovery (>3 months), the nerve may exhibit endoneurial fibrosis, decreased axon density (visible on Bielschowsky silver stain), and occasional regenerating clusters (small, thinly myelinated axons grouped together).
Staining Profile
| Stain | Finding | Interpretation |
|---|---|---|
| Hematoxylin and eosin | Perivascular lymphocytic cuffing, edema | Active inflammation |
| Luxol fast blue-Cresyl violet | Pale, fragmented myelin sheaths | Demyelination |
| Bielschowsky silver | Reduced axon count, axonal swelling | Axonal degeneration |
| S-100 immunostain | Loss of Schwann cells in affected segments | Schwann cell injury |
| CD3 / CD68 immunohistochemistry | T lymphocytes and macrophages in endoneurium | Immune-mediated attack |
Differential Histology
- Ramsay Hunt syndrome (varicella-zoster virus): Ganglionitis with intranuclear eosinophilic inclusion bodies (Cowdry type A) in satellite cells; positive VZV PCR on nerve tissue or vesicular fluid.
- Lyme neuroborreliosis: Perineural lymphoplasmacytic infiltration with spirochetes visible on modified Dieterle silver stain; positive Borrelia PCR on CSF.
- Sarcoidosis: Non-caseating granulomas with epithelioid histiocytes surrounding nerve fascicles; elevated serum angiotensin-converting enzyme.
Pearl: The histologic hallmark of Bell palsy is a sporadic, monophasic, immune-mediated demyelinating neuritis confined to the intratemporal facial nerve, without viral inclusions or granulomas; the absence of these features helps exclude Ramsay Hunt syndrome and sarcoidosis [15]C4.
Development (Brief Embryology)
- ▸The facial nerve (CN VII) arises from the second branchial arch during week 4; its motor nucleus forms in the caudal pons while the nervus intermedius derives from the epibranchial placode.
- ▸The bony fallopian canal ossifies from the otic capsule starting at week 16; its labyrinthine segment (0.68 mm) is the narrowest and most common site of entrapment in Bell palsy.
- ▸Developmental arrest of the facial nucleus can cause Möbius syndrome, Duane retraction syndrome, or isolated lower lip palsy, distinct from perinatal Bell palsy.
The seventh cranial nerve develops from the second branchial arch (hyoid arch) during the fourth week of gestation [20]D5. Its motor nucleus forms in the caudal pons, while the nervus intermedius, carrying taste from the anterior two-thirds of the tongue and parasympathetic fibers to the submandibular, sublingual, and lacrimal glands, originates from the adjacent geniculate ganglion, itself derived from the epibranchial placode [20]D5.
Key developmental steps
By the fifth to sixth week, the facial nerve motor fibers exit the brainstem and course toward the second arch mesenchyme. The nerve becomes closely associated with the stapedius muscle and the posterior belly of the digastric, both arch-derived, and its extratemporal branches arborize to supply the muscles of facial expression [20]D5. The chorda tympani, a branch of the nervus intermedius, joins the lingual nerve (mandibular division of CN V) at week 7, reflecting its second-arch gating to the tongue [20]D5.
The fallopian canal
The bony fallopian canal (canalis nervi facialis) ossifies from the otic capsule of the temporal bone beginning at week 16 and remains incomplete at birth; its slow postnatal maturation may contribute to the nerve's vulnerability to compression during inflammation, such as in Bell palsy [20]D5. The narrowest segment of the canal, the labyrinthine segment, with a diameter of 0.68 mm in adults, is the most common site of entrapment in idiopathic palsy [20]D5.
Congenital implications
Developmental arrest or aberrant migration can produce Möbius syndrome (agenesis of the facial nucleus with lateral gaze palsy), Duane retraction syndrome (co-contracting lateral rectus), or isolated unilateral lower lip palsy (congenital absence of depressor anguli oris) [20]D5. These must be distinguished from perinatal-acquired Bell palsy, which typically spares the forehead and resolves spontaneously [19]B2b.
Pearl: The facial nerve's long intrapetrous course within the fallopian canal, the narrowest segment measuring approximately 0.68 mm, is a consequence of its second-arch embryology and ossifying encapsulation by the otic capsule, explaining both idiopathic palsy and congenital synkinesis [20]D5.
Variations & Anomalies
- ▸Aberrant facial nerve regeneration produces three main synkinesis patterns: ocular-oral, oral-ocular, and pseudoptosis with synkinetic eyelid closure.
- ▸Hemifacial spasm with neuropathic otalgia is a rare but distinct syndrome seen in patients with underlying rheumatic disease (e.g., Sjögren syndrome).
- ▸Botulinum toxin A (1.25-5 U Botox) is first-line therapy; epineurectomy of the facial nerve trunk or preseptal orbicularis oculi resection are surgical options for refractory cases.
Aberrant facial nerve regeneration after Bell palsy produces a spectrum of synkinetic and spasmodic phenomena that are both diagnostically and therapeutically important. These anomalies are not true anatomical variants at baseline but are acquired functional reorganizations following nerve injury; they affect up to 30-40% of patients with incomplete recovery and can mimic or coexist with other neurological disorders.
Synkinesis Patterns
Synkinesis, involuntary contraction of one muscle group triggered by volitional movement of another, is the hallmark of aberrant regeneration. Three common patterns predominate:
- Ocular-oral synkinesis: eye closure triggers mouth corner elevation or narrowing of the palpebral fissure (Marin-Amat syndrome: involuntary eyelid closure upon jaw opening) .
- Oral-ocular synkinesis: mouth movement (e.g., smiling, puffing cheeks) provokes ipsilateral eyelid closure .
- Ptosis with synkinesis (pseudoptosis): the eyelid droops in primary gaze but actually elevates on attempted eye closure because the levator is paradoxically activated . True ptosis must be distinguished from this pseudoptosis.
Hemifacial Spasm and Pain Syndromes
Rarely, aberrant regeneration produces hemifacial spasm, involuntary, unilateral, synchronous contractions of facial muscles, typically accompanied by severe neuropathic otalgia (burning, allodynic pain) and vertigo. This triad (facial weakness → otalgia → hemifacial spasm) has been reported in patients with underlying rheumatic disease, especially Sjögren syndrome and rheumatoid arthritis . The mechanism is thought to involve ephaptic cross-talk at sites of demyelination and aberrant sprouting within the facial nerve trunk or its branches.
Diagnostic Tools and
| Anomaly | Diagnosis | First-line Treatment | Second-line / Surgical Options |
|---|---|---|---|
| Ocular-oral synkinesis | Clinical exam; EMG confirms aberrant co-contraction | Botulinum toxin A (Botox) 2.5-5 U per injection site into involved OOM | Epineurectomy of facial nerve trunk (FNT) under intraoperative EMG guidance |
| Oral-ocular synkinesis | Clinical exam; video recording to document trigger | Botulinum toxin A 2.5-5 U into pretarsal OOM | Resection of preseptal OOM (preserving pretarsal and orbital OOM) to maintain eyelid closure |
| Pseudoptosis | Examination: lid elevates on eye closure | Botulinum toxin A 1.25-2.5 U into medial and lateral pretarsal OOM | Levator advancement (if true ptosis confirmed) or OOM resection |
| Hemifacial spasm + otalgia | Clinical triad; MRI/MRA to exclude vascular compression | Treat underlying rheumatic disease; gabapentin or pregabalin for neuropathic pain | Consider carbamazepine or baclofen; botulinum toxin for spasm; neurosurgical consultation for refractory cases |
Botulinum toxin remains the first-line pharmacotherapy for all synkinesis variants, with low doses (1.25-5 U Botox) into the target orbicularis oculi muscle producing improvement lasting 3-4 months . For patients refractory to injections, epineurectomy of the facial nerve trunk has shown benefit in reducing oral-ocular and oculo-oral synkinesis in small case series; the procedure targets aberrant connections identified by preoperative ultrasonography and intraoperative abnormal muscle response monitoring . Alternatively, focal resection of the preseptal orbicularis oculi muscle (sparing the pretarsal and orbital portions) treats synkinetic eyelid closure without compromising voluntary eye closure .
Infection-Associated Variations
SARS-CoV-2 infection has been temporally associated with Bell palsy and its anomalous sequelae. In a Sri Lankan surveillance study, Bell palsy was the most common neurological disorder among -associated neurological presentations, with some patients developing persistent synkinesis during recovery . Whether the pandemic strain of SARS-CoV-2 produces a distinct pattern of aberrant regeneration remains unknown, but clinicians should maintain vigilance for atypical post-viral facial nerve anomalies.
Pearl: Synkinesis and pseudoptosis after Bell palsy are often mistaken for new neurological disease; a careful history, noting that involuntary movements occur only with voluntary facial actions, and low-dose botulinum toxin injections (1.25-5 U) into the involved orbicularis oculi muscle provide both confirmatory diagnosis and effective therapy in most patients .
Surface Anatomy & Imaging Correlation
- ▸Contrast-enhanced MRI of the facial nerve is the imaging modality of choice when secondary causes are suspected; enhancement of the geniculate ganglion is the most common finding in acute Bell palsy.
- ▸Routine MRI is not indicated for typical Bell palsy; the yield of alternative diagnoses is <2%, and imaging should be reserved for atypical features or lack of improvement after 3 months.
- ▸Surface landmarks (stylomastoid foramen, parotid gland) guide clinical examination and surgical approaches but are not diagnostic.
Surface Landmarks
The facial nerve exits the skull base at the stylomastoid foramen, a bony aperture located between the mastoid process and the styloid process. From there, it courses anteriorly into the parotid gland, where it divides into its five terminal branches (temporal, zygomatic, buccal, marginal mandibular, and cervical). Palpation of the mastoid tip and the angle of the mandible provides a surface guide to the nerve's extracranial course. In Bell palsy, tenderness over the stylomastoid foramen may be present, but this finding is neither sensitive nor specific [27]B2b.
Imaging Modalities
Contrast-enhanced magnetic resonance imaging (MRI) of the internal auditory canal and facial nerve is the imaging modality of choice when secondary causes are suspected [27]B2b[29]B2b. High-resolution T1-weighted sequences with fat suppression after gadolinium administration best demonstrate nerve enhancement. Computed tomography (CT) is reserved for evaluating bony anatomy (e.g., temporal bone fractures, ) and is not routinely indicated for Bell palsy [27]B2b.
MRI Findings in Bell Palsy
In acute Bell palsy (within 7 days of symptom onset), contrast-enhanced MRI reveals abnormal enhancement of the affected facial nerve in 85% to 90% of patients [29]B2b. The enhancement most commonly involves the geniculate ganglion, followed by the labyrinthine and tympanic segments [29]B2b. The intracanalicular segment may also enhance. This pattern reflects inflammation and breakdown of the blood-nerve barrier. However, enhancement is not pathognomonic; it can occur in other inflammatory, neoplastic, or infectious conditions (e.g., Ramsay Hunt syndrome, schwannoma, sarcoidosis) [27]B2b[29]B2b.
| Segment | Frequency of Enhancement in Bell Palsy | Clinical Relevance |
|---|---|---|
| Geniculate ganglion | ~80% | Most common site; correlates with taste disturbance |
| Labyrinthine | ~60% | Narrowest segment; vulnerable to compression |
| Tympanic | ~50% | May mimic middle ear pathology |
| Intracanalicular | ~40% | Must be distinguished from |
Role of Imaging in Differential Diagnosis
Routine MRI for all patients with Bell palsy is not recommended because the yield of alternative diagnoses is low (1.7% in a large multicenter study) [27]B2b. Imaging is indicated when:
- Atypical features are present (e.g., bilateral palsy, recurrent palsy, slow progression >3 weeks, other )
- No improvement occurs after 3 months of conservative therapy
- Suspicion of secondary causes such as Ramsay Hunt syndrome (vesicles in the ear canal), temporal bone fracture, parotid tumor, or intracranial mass (e.g., hemangioma, ganglion cyst) [28]C4[30]C4
In children presenting with acute facial palsy, the differential includes stroke; MRI with diffusion-weighted imaging can distinguish ischemic stroke from Bell palsy [19]B2b.
Pearl: In acute Bell palsy, contrast-enhanced MRI shows facial nerve enhancement in up to 90% of cases, but the diagnosis remains clinical; imaging is reserved for atypical presentations or failure to improve, where it identifies an alternative cause in fewer than 2% of patients [27]B2b[29]B2b.
Clinical Correlations
- ▸Bell palsy is the most common stroke mimic in children and adults; distinguishing upper vs lower motor neuron facial weakness (forehead involvement) is the critical first step [16].
- ▸Oral prednisolone 1 mg/kg/day for 7 days is the only evidence-based treatment; adding antivirals provides marginal benefit only in severe cases (NNT = 12) [34, 32].
- ▸ENoG showing >90% denervation within 14 days identifies candidates for surgical decompression, but the procedure is rarely indicated and benefit is modest [1, 31].
Examination Findings and Diagnostic Maneuvers
The classic presentation, acute onset of unilateral lower motor neuron facial weakness, is a clinical diagnosis. On inspection, the brow is flattened, the nasolabial fold is effaced, and the corner of the mouth droops. Ask the patient to raise both eyebrows, close the eyes tightly, puff the cheeks, and show the teeth. In Bell palsy, the forehead is involved (unlike in upper motor neuron weakness from stroke, where the forehead is spared). The palpebral fissure is wider on the affected side, and the eye may not close fully (lagophthalmos), placing the cornea at risk for exposure keratopathy [31]A1c.
Red Flags and Stroke Mimics
Bell palsy is the most common stroke mimic in both adults and children [16]A1c. Any patient presenting with acute facial weakness must be rapidly assessed for central (upper motor neuron) signs. Key distinguishing features: forehead sparing, isolated lower-face weakness, arm or leg drift, speech disturbance, or acute headache with vomiting point to stroke, not Bell palsy [16]A1c. In children, seizures with postictal paralysis and complicated migraine also mimic Bell palsy; imaging (CT or MRI) is indicated when the history or neurological examination is atypical [16]A1c.
Phenotypic Variants and Syndromes
| Variant | Key Features | Implications |
|---|---|---|
| Ramsay Hunt syndrome | Vesicular rash in the ear canal or auricle (zoster oticus), severe ear pain, hearing loss, vertigo | Caused by varicella-zoster virus reactivation; requires antiviral therapy ( 800 mg 5×/d × 7-10 days) plus corticosteroids; prognosis worse if untreated [31]A1c |
| Bilateral facial palsy | Weakness of both sides of the face (~0.3% of all facial palsy) | Think: Guillain-Barré syndrome, sarcoidosis, , HIV, meningitis. Each cause has distinct [31]A1c |
| Recurrent Bell palsy | ≥2 episodes of idiopathic unilateral facial weakness | Evaluate for autoimmune or structural causes (e.g., Melkersson-Rosenthal syndrome, familial Bell palsy); MRI with gadolinium to rule out schwannoma or perineural tumor spread |
Electrophysiological Testing and Prognostication
Electroneuronography (ENoG) and needle electromyography (EMG) provide objective prognostic data. A compound muscle action potential (CMAP) amplitude ≤10% of the unaffected side (denervation ≥90%) within the first 14 days correlates with poor recovery and may prompt consideration of surgical decompression [1]A1a. Voluntary motor unit potentials on needle EMG within the first 10 days portend a favorable outcome. Recovery begins within the first 3 weeks in 85% of patients; if no improvement by 4 months, the chance of complete return to normal is low [31]A1c.
Corticosteroid Therapy Evidence
Oral prednisolone 1 mg/kg/day (maximum 60-80 mg/day) for 7 days (no taper needed) is the standard of care [32]A1a. A network meta-analysis found no significant difference in recovery between oral prednisolone and single-dose intravenous (OR 1.07, 95% CI 0.81-1.42) [32]A1a. In children, a randomized trial showed that at 6 months, 98% of children treated with prednisolone had recovered vs 93% with placebo (absolute difference 5%, NNT = 20, not statistically significant; 95% CI for difference -1% to 12%) [35]A1b. Short-course corticosteroids are generally well-tolerated in children; a meta-analysis found that the risk of vomiting was increased (RR 2.18, 95% CI 1.06-4.50, NNH = 14), but serious adverse events were rare [18]A1a.
Antiviral Therapy: Limited Role
Antiviral therapy alone (acyclovir or ) is not superior to placebo for recovery [34]A1a. Adding antivirals to steroids yields a marginal benefit only in severe Bell palsy (House-Brackmann grade IV-VI). A network meta-analysis of 11 trials (3393 patients) reported that the combination of corticosteroids plus an antiviral improved the odds of complete recovery at 3 months vs steroids alone (OR 1.48, 95% CI 1.02-2.14, NNT = 12) [34]A1a. For Ramsay Hunt syndrome, the combination is clearly indicated. Routine monotherapy with antivirals for idiopathic Bell palsy is not recommended [31]A1c.
Surgical Decompression: Narrow Indication
Facial nerve decompression (FND) is controversial and rarely performed. In a meta-analysis of 7 studies, the odds of complete recovery (House-Brackmann grade I) after FND vs conservative management was OR 4.7 (95% CI 1.4-16.4), but the evidence is limited by small sample sizes, selection bias, and the natural recovery rate of 85% [1]A1a. Current guidelines reserve FND for patients with complete paralysis (House-Brackmann grade VI) and >90% degeneration on ENoG within 14 days of onset, and only if performed within 2-3 weeks of symptom onset [1]A1a[31]A1c. Beyond this window, decompression offers no benefit over spontaneous recovery [31]A1c.
Adverse Events and Vaccine Associations
Short-course corticosteroids are safe. In a systematic review of 30 RCTs (9420 children), short-term corticosteroids (≤14 days) were not associated with serious infections or growth suppression [18]A1a. However, Bell palsy has been reported as an adverse event after vaccination, particularly with the tozinameran (BNT162b2) SARS-CoV-2 vaccine. A meta-analysis of 9 studies found a modestly increased risk: incidence rate ratio 2.50 (95% CI 1.30-4.80) for mRNA vaccines compared to unvaccinated controls [33]B2a. The absolute risk is low, approximately 0.5 to 1 cases per 10,000 vaccine recipients, and the natural incidence of Bell palsy is 15-30 per 100,000 per year [33]B2a.
Eye Protection
Lagophthalmos requires immediate corneal protection. Prescribe artificial tears (preservative-free, every 1-2 hours while awake) and a lubricating ointment at bedtime. Tape the eye closed at night or use a moisture chamber. If corneal exposure persists, consider a temporary tarsorrhaphy or botulinum toxin injection to induce protective ptosis [31]A1c.
Pearl: Bell palsy is a clinical diagnosis of exclusion, confirm that forehead muscles are involved (lower motor neuron), document the House-Brackmann grade, start prednisolone 1 mg/kg/day within 72 hours of onset, protect the eye, and reserve antivirals for severe cases or Ramsay Hunt syndrome; routine imaging is unnecessary if the history and exam are classic [16]A1c[31]A1c[32]A1a[34]A1a.
| Variant | Key Features | Implications |
|---|---|---|
| Ramsay Hunt syndrome | Vesicular rash in ear canal/auricle, ear pain, hearing loss, vertigo | Requires acyclovir 800 mg 5×/d × 7-10 d + steroids; worse prognosis if untreated [31]A1c |
| Bilateral facial palsy | Bilateral lower motor neuron facial weakness (rare) | Think: Guillain-Barré, sarcoidosis, Lyme disease, HIV, meningitis [31]A1c |
| Recurrent Bell palsy | ≥2 episodes of idiopathic unilateral weakness | Evaluate for autoimmune or structural cause; MRI with gadolinium to exclude schwannoma [31]A1c |
Eponyms & Nomenclature
- ▸Bell palsy is named after Sir Charles Bell; the term should be reserved for idiopathic acute peripheral facial nerve palsy after excluding other causes.
- ▸Alternative terms include idiopathic facial nerve palsy and acute peripheral facial palsy; the non-possessive form is preferred in contemporary medical writing.
The eponym "Bell palsy" honors Sir Charles Bell (1774-1842), the Scottish anatomist who first described the clinical features of acute peripheral facial nerve paralysis [17]D5. The condition is also referred to as idiopathic facial nerve palsy or , terms that emphasize the unknown etiology and the anatomical localization. The possessive form "Bell's palsy" remains common in patient communication and older literature, but contemporary medical writing increasingly uses the non-possessive "Bell palsy" to align with standard eponym conventions [17]D5.
Synonyms and Preferred Terminology
| Term | Context |
|---|---|
| Bell palsy / Bell's palsy | Most widely recognized eponym; used in clinical practice and guidelines |
| Idiopathic facial nerve palsy | Preferred in academic writing to denote unknown cause |
| Acute peripheral facial palsy | Emphasizes acute onset and peripheral nerve involvement |
Diagnostic Pitfall
The eponym is frequently misapplied to any acute facial paralysis. However, Bell palsy is a diagnosis of exclusion; the term should be reserved for idiopathic cases after ruling out stroke, Ramsay Hunt syndrome, , and other structural causes [38]D5. Erroneous use of the eponym can delay appropriate workup and treatment [38]D5.
Pearl: The eponym "Bell palsy" should be used only for idiopathic acute peripheral facial nerve palsy after excluding alternative etiologies; the non-possessive form is preferred in current medical literature [17]D5[38]D5.
References
- [1]
Lee SY, Seong J, Kim YH. “Clinical Implication of Facial Nerve Decompression in Complete Bell's Palsy: A Systematic Review and Meta-Analysis.” Clinical and experimental otorhinolaryngology (2019). PMID: 31487771 ↗
L1SR_OBSCited in: Definition & Classification, Clinical Correlations - [2]
Babl FE, Herd D, Borland ML et al.. “Efficacy of Prednisolone for Bell Palsy in Children: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial.” Neurology (2022). PMID: 36008143 ↗
L1RCTCited in: Definition & Classification - [3]
Tuncay F, Borman P, Taşer B et al.. “Role of electrical stimulation added to conventional therapy in patients with idiopathic facial (Bell) palsy.” American journal of physical medicine & rehabilitation (2015). PMID: 25171666 ↗
L1RCTCited in: Definition & Classification - [4]
Breitling V, Leha A, Schiller S et al.. “Association of Overweight and Obesity With Bell Palsy in Children.” Pediatric neurology (2022). PMID: 36508882 ↗
L3OTHERCited in: Definition & Classification - [5]
Gronseth GS, Paduga R. “Evidence-based guideline update: steroids and antivirals for Bell palsy: report of the Guideline Development Subcommittee of the American Academy of Neurology.” Neurology (2012). PMID: 23136264 ↗
L1OTHERCited in: Definition & Classification - [6]
Pavlidis P, Cámara RJA, Kekes G et al.. “Bilateral taste disorders in patients with Ramsay Hunt syndrome and Bell palsy.” Annals of neurology (2018). PMID: 29537615 ↗
L2OTHERCited in: Gross Structure & Morphology, Blood Supply, Innervation & Lymphatic Drainage - [7]
Klingner CM, Volk GF, Brodoehl S et al.. “Time course of cortical plasticity after facial nerve palsy: a single-case study.” Neurorehabilitation and neural repair (2011). PMID: 21875890 ↗
L4CASE_REPORTCited in: Gross Structure & Morphology - [8]
Çaytemel B, Kara H, Sönmez S et al.. “Investigation of the Effects of the Timing of Decompression and Topical Mitomycin-C Application on Nerve Regeneration in a Rat Model of Bell's Palsy.” Turkish archives of otorhinolaryngology (2025). PMID: 40844364 ↗
L2OTHERCited in: Gross Structure & Morphology - [9]
Selvi F, Guven E, Mutlu D. “Clinical management of microstomia due to the static treatment of facial paralysis and oral rehabilitation with dental implants.” The Journal of craniofacial surgery (2011). PMID: 21558911 ↗
L5CASE_REPORTCited in: Relations, Borders & Spaces - [10]
Azuma T, Nakamura K, Takahashi M et al.. “Electroneurography in the acute stage of facial palsy as a predictive factor for the development of facial synkinesis sequela.” Auris, nasus, larynx (2017). PMID: 28966005 ↗
L3OTHERCited in: Relations, Borders & Spaces - [11]
Dvorin EL, Ebell MH. “Short-Term Systemic Corticosteroids: Appropriate Use in Primary Care.” American family physician (2020). PMID: 31939645 ↗
L5REVIEW_NARRATIVECited in: Blood Supply, Innervation & Lymphatic Drainage - [12]
Klein NP, Lewis N, Goddard K et al.. “Surveillance for Adverse Events After COVID-19 mRNA Vaccination.” JAMA (2021). PMID: 34477808 ↗
L2OTHERCited in: Blood Supply, Innervation & Lymphatic Drainage - [13]
Mahmud N, Reinisch W, Patel M et al.. “Adverse Events Related to SARS-CoV-2 Vaccine in a Nationwide Cohort of Patients With Inflammatory Bowel Disease.” Clinical and translational gastroenterology (2023). PMID: 36508224 ↗
L2OTHERCited in: Blood Supply, Innervation & Lymphatic Drainage - [14]
Mackay MT, Churilov L, Donnan GA et al.. “Performance of bedside stroke recognition tools in discriminating childhood stroke from mimics.” Neurology (2016). PMID: 27178704 ↗
L2OTHERCited in: Blood Supply, Innervation & Lymphatic Drainage - [15]
Lee S, Lew H. “Ophthalmologic Clinical Features of Facial Nerve Palsy Patients.” Korean journal of ophthalmology : KJO (2019). PMID: 30746906 ↗
L4OTHERCited in: Microscopic & Histological Notes - [16]
Robertson RL, Palasis S, Rivkin MJ et al.. “ACR Appropriateness Criteria® Cerebrovascular Disease-Child.” Journal of the American College of Radiology : JACR (2020). PMID: 32370977 ↗
L1GUIDELINECited in: Development (Brief Embryology), Clinical Correlations - [17]
Schwartz SR, Jones SL, Getchius TS et al.. “Reconciling the clinical practice guidelines on Bell's palsy from the AAO-HNSF and the AAN.” Neurology (2014). PMID: 24793182 ↗
L5GUIDELINECited in: Development (Brief Embryology), Eponyms & Nomenclature - [18]
Lima JP, Chowdhury SR, Tangamornsuksan W et al.. “Adverse Events Following Short-Course Systemic Corticosteroids Among Children and Adolescents: A Systematic Review and Meta-Analysis.” JAMA network open (2025). PMID: 41026484 ↗
L1SR_OBSCited in: Development (Brief Embryology), Clinical Correlations - [19]
Mackay MT, Chua ZK, Lee M et al.. “Stroke and nonstroke brain attacks in children.” Neurology (2014). PMID: 24658929 ↗
L2SR_OBSCited in: Development (Brief Embryology), Surface Anatomy & Imaging Correlation - [20]
Rajangam J, Lakshmanan AP, Rao KU et al.. “Bell Palsy: Facts and Current Research Perspectives.” CNS & neurological disorders drug targets (2024). PMID: 36959147 ↗
L5REVIEW_NARRATIVECited in: Development (Brief Embryology) - [21]
Anh VTQ, Kim J, Jang S et al.. “Ptosis With Aberrant Facial Nerve Regeneration Following Bell Palsy.” The Journal of craniofacial surgery (Unknown). PMID: 33229993 ↗
L4CASE_REPORTCited in: Variations & Anomalies - [22]
Lai CS, Lu SR, Yang SF et al.. “Surgical treatment of the synkinetic eyelid closure in Marin-Amat syndrome.” Annals of plastic surgery (2011). PMID: 21659851 ↗
L4CASE_REPORTCited in: Variations & Anomalies - [23]
Chang T, Wijeyekoon R, Keshavaraj A et al.. “Neurological disorders associated with COVID-19 in Sri Lanka.” BMC neurology (2023). PMID: 37794324 ↗
L2OTHERCited in: Variations & Anomalies - [24]
Wei X, Chang B, Li S. “Epineurectomy of Facial Nerve Trunk for Refractory Oral-Ocular and Oculo-Oral Synkinesis Following Bell Palsy.” The Journal of craniofacial surgery (Unknown). PMID: 34260463 ↗
L4OTHERCited in: Variations & Anomalies - [25]
McElhinny ER, Reich I, Burt B et al.. “Treatment of pseudoptosis secondary to aberrant regeneration of the facial nerve with botulinum toxin type A.” Ophthalmic plastic and reconstructive surgery (2013). PMID: 23467287 ↗
L4OTHERCited in: Variations & Anomalies - [26]
Birnbaum J. “Facial Weakness, Otalgia, and Hemifacial Spasm: A Novel Neurological Syndrome in a Case-Series of 3 Patients With Rheumatic Disease.” Medicine (2015). PMID: 26447997 ↗
L4CASE_REPORTCited in: Variations & Anomalies - [27]
Savary T, Fieux M, Douplat M et al.. “Incidence of Underlying Abnormal Findings on Routine Magnetic Resonance Imaging for Bell Palsy.” JAMA network open (2023). PMID: 37079301 ↗
L2RCTCited in: Surface Anatomy & Imaging Correlation - [28]
Mumert ML, Altay T, Shelton C et al.. “Ganglion cyst of the temporomandibular joint with intracranial extension in a patient presenting with seventh cranial nerve palsy.” Journal of neurosurgery (2011). PMID: 22117183 ↗
L4CASE_REPORTCited in: Surface Anatomy & Imaging Correlation - [29]
Seok JI, Park JH, Park JA et al.. “Contrast-enhanced MRI findings of patients with acute Bell palsy within 7 days of symptom onset: A retrospective study.” Medicine (2023). PMID: 38050278 ↗
L2COHORTCited in: Surface Anatomy & Imaging Correlation - [30]
Zamil DH, Fernandez JK, Brown DN et al.. “Intracranial hemangioma-associated cranial nerve VII palsy treated with propranolol in an infant with possible PHACE syndrome.” Pediatric dermatology (2022). PMID: 36271758 ↗
L4CASE_REPORTCited in: Surface Anatomy & Imaging Correlation - [31]
Pauna HF, Silva VAR, Lavinsky J et al.. “Task force of the Brazilian Society of Otology - evaluation and management of peripheral facial palsy.” Brazilian journal of otorhinolaryngology (2023). PMID: 38377729 ↗
L1GUIDELINECited in: Clinical Correlations - [32]
Abdu SH, Alsubhi AH, Alzahrani A et al.. “Comparison of oral versus intravenous steroid in the management of Bell's palsy: a systematic review and meta-analysis of randomized clinical trials.” European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery (2023). PMID: 37940744 ↗
L1SR_OBSCited in: Clinical Correlations - [33]
Rafati A, Pasebani Y, Jameie M et al.. “Association of SARS-CoV-2 Vaccination or Infection With Bell Palsy: A Systematic Review and Meta-analysis.” JAMA otolaryngology-- head & neck surgery (2023). PMID: 37103913 ↗
L2SR_OBSCited in: Clinical Correlations - [34]
Cao J, Zhang X, Wang Z. “Effectiveness comparisons of antiviral treatments for Bell palsy: a systematic review and network meta-analysis.” Journal of neurology (2021). PMID: 33674936 ↗
L1SR_OBSCited in: Clinical Correlations - [35]
Babl FE, Herd D, Borland ML et al.. “Facial Function in Bell Palsy in a Cohort of Children Randomized to Prednisolone or Placebo 12 Months After Diagnosis.” Pediatric neurology (2024). PMID: 38320457 ↗
L1RCTCited in: Clinical Correlations - [36]
Liu EY, Smith LM, Ellis AK et al.. “Quadrivalent human papillomavirus vaccination in girls and the risk of autoimmune disorders: the Ontario Grade 8 HPV Vaccine Cohort Study.” CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne (2018). PMID: 29807937 ↗
L2COHORTCited in: Eponyms & Nomenclature - [37]
Dalrymple SN, Row JH, Gazewood JD. “Bell's Palsy.” Primary care (2025). PMID: 39939082 ↗
L5REVIEW_NARRATIVECited in: Eponyms & Nomenclature - [38]
George E, Richie MB, Glastonbury CM. “Facial Nerve Palsy: Clinical Practice and Cognitive Errors.” The American journal of medicine (2020). PMID: 32445717 ↗
L5REVIEW_NARRATIVECited in: Eponyms & Nomenclature